Atypical femur fractures, a rare adverse event of bisphosphonates in oncology: Case report

Bisphosphonates are one of the fundamental pillars in the treatment of bone morbidities in patients with different types of solid tumors.1-3 However, despite the experience that we have accumulated during decades, there are adverse events such as atypical fractures (AF) that due to their low frequency can go unnoticed and might not receive adequate management. There are few reports in the literature about AF in cancer treatments. We present a case of a patient with metachronous breast cancer and bone metastases at initial diagnosis, currently in remission, who presents AF of the femur after receiving bisphosphonates for 8 years.